Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

hVIVO acquired CHIMagents in July 2021, further strengthening our capabilities in human challenge studies.

hVIVO is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge trials.

We provide end-to-end early clinical development services for our broad and long-standing client base of global biopharma companies.

For more information about our company and services:

Go to hVIVO